NASDAQ:BLUE - bluebird bio Stock Price, Forecast & News

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio Inc (NASDAQ:BLUE) issued its quarterly earnings data on Tuesday, February, 18th. The biotechnology company reported ($4.04) EPS for the quarter, missing analysts' consensus estimates of ($3.79) by $0.25. The biotechnology company had revenue of $10 million for the quarter, compared to analyst estimates of $8.23 million. bluebird bio had a negative return on equity of 42.29% and a negative net margin of 1,326.56%. The company's revenue was down 47.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.72) earnings per share. View bluebird bio's Earnings History.

bluebird bio is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for bluebird bio.

20 brokers have issued twelve-month price targets for bluebird bio's stock. Their forecasts range from $94.00 to $195.00. On average, they expect bluebird bio's stock price to reach $131.94 in the next year. This suggests a possible upside of 64.0% from the stock's current price. View Analyst Price Targets for bluebird bio.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for bluebird bio.

News coverage about BLUE stock has been trending neutral this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. bluebird bio earned a news sentiment score of 0.1 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for bluebird bio.

Some companies that are related to bluebird bio include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Crispr Therapeutics (CRSP) and Momenta Pharmaceuticals (MNTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include Opko Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Celgene (CELG), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU) and ABIOMED (ABMD).

bluebird bio's stock is owned by a number of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (12.25%), FMR LLC (11.06%), Capital World Investors (9.52%), Sands Capital Management LLC (5.74%), Victory Capital Management Inc. (3.35%) and Victory Capital Management Inc. (3.30%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory, Susanna Gatti High and William D Baird III. View Institutional Ownership Trends for bluebird bio.

BLUE stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Baillie Gifford & Co., FMR LLC, Capital International Inc. CA, Eaton Vance Management, Capital Bank & Trust Co, Bank of America Corp DE and Franklin Resources Inc.. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, David Davidson, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Nick Leschly, Philip D Gregory and William D Baird III. View Insider Buying and Selling for bluebird bio.

BLUE stock was bought by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Casdin Capital LLC, State Street Corp, Victory Capital Management Inc., First Trust Advisors LP, Victory Capital Management Inc., Nikko Asset Management Americas Inc. and Sumitomo Mitsui Trust Holdings Inc.. View Insider Buying and Selling for bluebird bio.

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BLUE stock can currently be purchased for approximately $80.45.

bluebird bio has a market capitalization of $4.45 billion and generates $54.58 million in revenue each year. The biotechnology company earns $-555,630,000.00 in net income (profit) each year or ($10.68) on an earnings per share basis. bluebird bio employs 764 workers across the globe.View Additional Information About bluebird bio.

The official website for bluebird bio is http://www.bluebirdbio.com/.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]